(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and Monday and not separately reported by Alliance News: Read More
(Alliance News) - Aptamer Group PLC on Thursday said it has partnered with Kairos Biotech Ltd for Optimer+ transplant rejection therapies. Read More
(Alliance News) - Aptamer Group PLC on Monday said it filed a patent application aimed at supporting the next stages of commercial advancement with Unilever PLC. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Aptamer Group PLC shares rose on Monday, after it noted progression on its contract with Unilever PLC. Read More
(Alliance News) - Aptamer Group PLC on Tuesday said its new Optimer+ platform delivers improved results compared to standard binders. Read More
(Alliance News) - Aptamer Group PLC on Thursday said it has entered the second phase of developing Optimer binders for the early diagnosis of Alzheimer's disease alongside Neuro-Bio Ltd. Read More
(Alliance News) - Aptamer Group PLC on Monday said it will miss its half-year revenue expectations as a result of weak customer demand. Read More
Aptamer Group PLC - York-based biotech firm - Signs material agreement with unnamed biotechnology company, focused on developing genetic medicines. Aptamer will use its platform to discover Optimer binders to enable specific targeting of genetic medicines to specific cell types. Says it will receive up to GBP553,000 in development fees for discovering and developing the Optimer binders. Work is expected to start shortly and is expected to be completed within the current financial year. Optimer binders are a novel class of molecules for selectively targeting new biomarkers and tissues. Chief Technical Officer Arron Tolley says: "This project builds on the work we have been doing in drug delivery since being refunded and supports the need for new delivery modalities within the genetic medicines space. Targeting oligonucleotide therapeutics beyond hepatocytes remains a challenge across the industry; we believe the properties of Optimers make them suitable for developing precision-guided therapies and that Optimer-targeted therapies may represent the next stage in targeted drug delivery." Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Stock prices in London closed mixed on Monday, whilst US markets opened higher, with investors continuing to digest hopes that interest rates have peaked. Read More
(Alliance News) - Aptamer Group PLC on Monday said revenue in its first financial half will be lower due to weaker customer confidence. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday. Read More
Aptamer Group PLC - York-based biotech firm - Raises GBP310,772 through the issue of around 28.3 million shares by way of a subscription and a placing to certain existing shareholders at 1.1p per share. Explains the fundraise was initiated following approaches from existing non-UK shareholders who could not be contacted in time to participate in the August 2023 fundraise and extended to take advantage of demand from other existing shareholders. Notes the fundraise includes a subscription by Adam Hargreaves, a non-executive director, for 5 million shares for a total investment of GBP55,000. Following this further investment, Hargreaves now holds a 4.8% stake in the company. In addition, Nicholas Slater, an existing investor spends GBP50,000 for around 4.5 million shares, taking his holding to 5.6% of the enlarged issued share capital. Net proceeds will be ringfenced to support research and development activities within the business, including the ongoing process improvements. R&D work was reduced as part of the company's new strategy to support cost-cutting in August. Read More
(Alliance News) - Aptamer Group PLC on Thursday announced a cost-cutting drive as it aims to break even within two years. Read More
(Alliance News) - Aptamer Group PLC on Thursday said it has signed two new contracts with an unnamed "top five pharma partner", valued up to GBP219,000. Read More
(Alliance News) - Stock prices in London were lower at midday on Monday, though European peers were on the rise, following favourable eurozone economic data. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday. Read More
(Alliance News) - Aptamer Group PLC announced that it had terminated its sale process after announcing it had conditionally completed a fundraise, while the company also revealed that its chair and interim chief executive officer & chief financial officer have both resigned. Read More